Why the study?
Does aliskiren reduce sitting systolic blood pressure and plasma renin activity in patients with mild to moderate hypertension?
Does aliskiren reduce sitting systolic blood pressure and plasma renin activity in patients with mild to moderate hypertension?
Aliskiren provides dose-dependent renin-angiotensin system blockade and blood pressure reduction comparable to irbesartan in patients with mild to moderate hypertension.
Answers are grounded in this paper and cite their sources.
Aliskiren matches irbesartan SBP reduction while suppressing PRA; confirms direct renin inhibition as an effective RAS blockade strategy in hypertension.
For several decades, the lack of oral availability and poor antihypertensive effects of renin inhibitors (RI), despite seemingly powerful inhibition of conventionally measured plasma renin activity (PRA), have discredited RI as cardiovascular drugs. Aliskiren is a novel orally effective RI with antihypertensive potency comparable to losartan or irbesartan. The present study investigated the effects of aliskiren and irbesartan on PRA, measured by the reliable antibody trapping technique, as well as on plasma active renin concentration (ARC) and sitting systolic blood pressure (SBP). In 569 patients with mild to moderate hypertension (baseline sphygmomanometric sitting blood pressure 152±12/99±4 mmHg, mean±SD), PRA and ARC, as well as SBP were measured before and after 8 weeks of treatment with once daily oral doses of aliskiren (150, 300 or 600mg), irbesartan 150mg or placebo. The effects of study treatments on PRA, ARC and SBP are summarized in the Table. PRA and ARC values are geometric means; SBP values are mean ± SD PRA and ARC values are geometric means; SBP values are mean ± SD Aliskiren reduced PRA by 69%, 71% and 75% at 150, 300 and 600mg respectively, while irbesartan doubled PRA. Most of the antihypertensive effect of aliskiren was obtained with the lowest dose, but higher doses slightly further decreased SBP. Aliskiren 150mg and irbesartan 150mg provided similar increases in ARC and hence comparably blocked the renin-angiotensin system (RAS), and the achieved SBP was also the same. Aliskiren 300mg and 600mg caused greater increases in ARC compared with irbesartan 150mg (p<0.05), and further decreases in SBP. The dose-dependent increases in ARC observed with aliskiren document increasing blockade of the RAS. In conclusion, aliskiren provides a parallel reduction in PRA and SBP, a dose-dependent blockade of the RAS and is at least as effective as irbesartan at comparable dosages (150mg).
No takes yet. Share an insight, caveat, or question.
Nussberger et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: